Baker Tilly and IBM MarketScan Come Together to Help Healthcare Companies Unlock Their Growth Potential With Real-World Evidence Strategies
- S&P 500, Nasdaq open higher; Amex, Honeywell weigh on Dow
- Snap (SNAP) Beats Q1 Estimates Amid 'Robust Ad Environment,' Analysts Raise Numbers and PTs
- Bitcoin sinks below $50,000 as cryptos stumble over Biden tax plans
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
CHICAGO--(BUSINESS WIRE)-- Leading advisory, tax and assurance firm Baker Tilly US, LLP (Baker Tilly) strengthens its capability to help healthcare and life sciences companies demonstrate the clinical and commercial value of their treatments, products, services and innovations, identify trends and see how they stack up against competitors – using Baker Tilly’s real-time real-world evidence library that now includes the data power of IBM.
Baker Tilly’s new licensing partnership provides clients with access to IBM MarketScan Research Databases, a suite of healthcare research data sets from one of the longest-running and largest collections of proprietary de-identified claims data for privately and publicly insured people in the U.S.
“We recognize the difficulty that life sciences companies have in gaining market entry/access for their newest innovations and then growing it into a standard of care. Adding the IBM MarketScan Research Databases to Baker Tilly’s current real-world evidence library including multi-year Medicare data and EMR systems mining enables us to provide our clients with a one-stop partnership for real-world evidence generation to facilitate successful market access initiatives,” said Darren Jones, Baker Tilly life sciences consulting principal.
The IBM MarketScan Research Databases includes diagnostic, procedural and economic data for more than 25 million patients covered by employer-sponsored private healthcare annually. Notably, the database can follow longitudinal multi-year patient journeys which can help pharmaceutical, medtech, health plan and healthcare provider organizations gain insight into episode-of-care and other value-based care market trends.
“These databases allows us to access real-time, real-world data for our clients to help them size markets, benchmark competitors and receive up-to-date information about other organizations’ profiles, market share, and performance metrics,” said David Gregory, MPA, FACHE, Baker Tilly healthcare consulting principal.
Research leveraging IBM MarketScan-based research has contributed to literature used to formulate policy decisions and help improve healthcare for Americans since 1990. An IBM Watson Health whitepaper notes that since then more than 2,400 articles have appeared in major peer-reviewed journals in the areas of:
- Health economics and outcomes research
- Economic burden of illness
- Comparative effectiveness research
Learn more about how Baker Tilly’s life sciences and healthcare clients can benefit from the IBM MarketScan Research Databases:
About Baker Tilly US, LLP (bakertilly.com)
Baker Tilly US, LLP (Baker Tilly) is a leading advisory, tax and assurance firm, providing clients a genuine coast-to-coast and global advantage with critical mass and top-notch talent in major regions of the U.S. and in many of the world’s leading financial centers – New York, London, San Francisco, Los Angeles and Chicago. Baker Tilly is an independent member of Baker Tilly International, a worldwide network of independent accounting and business advisory firms in 146 territories, with 36,000 professionals and a combined worldwide revenue of $3.9 billion. Visit bakertilly.com or join the conversation on LinkedIn, Facebook and Twitter.
Baker Tilly US, LLP is a member of the Baker Tilly International network, the members of which are separate and independent legal entities. Baker Tilly refers to the global network of accounting firms of Baker Tilly International Limited. Baker Tilly International Limited does not provide services to clients.
612 876 4891
Baker Tilly Media Relations
Source: Baker Tilly US, LLP
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academ
- Looking For Marijuana Stocks To Buy On Robinhood? 2 For Your Watchlist Next Week
- Helixmith Announces Poster Presentations at the 2021 American Academy of Pain Medicine Meeting